You are here

RAFT PHARMACEUTICALS LLC

Company Information
Address
6725 MESA RIDGE ROAD STE 260
SAN DIEGO, CA 92121-3938
United States



Information

UEI: KD1LJTFV7DN8

# of Employees: 4


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Targeting TLR4-lipid rafts to prevent postoperative pain

    Amount: $414,835.00

    PROJECT SUMMARY Postoperative pain is a prevalent source of pain requiring appropriate management to reduce its impact upon quality of life. Even with the availability of several analgesics, postopera ...

    STTRPhase I2023Department of Health and Human Services National Institutes of Health
  2. Targeting lipid rafts for treatment of asthma

    Amount: $999,991.00

    PROJECT SUMMARY Patients with severe asthma who display persistent bronchoconstriction and/or reduced lung function despite available bronchodilator, corticosteroid and Th2-targeting therapy develop s ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  3. AAV-AIBP Therapy for Alzheimer's Disease

    Amount: $500,000.00

    PROJECT SUMMARY Therapy for Alzheimer’s disease and related dementias (AD/ADRD), slow-progressing neurodegenerative diseases, remains elusive. Therapeutic approaches focusing on beta amyloid (Aβ) r ...

    STTRPhase I2022Department of Health and Human Services National Institutes of Health
  4. Novel biologic to treat chemotherapy-induced neuropathic pain

    Amount: $2,049,964.00

    PROJECT SUMMARY Chemotherapy-induced peripheral neuropathy (CIPN) has a profound negative impact on quality of life of nearly 70% of cancer patients receiving chemotherapy. While systemic administrati ...

    SBIRPhase II2022Department of Health and Human Services National Institutes of Health
  5. Targeting lipid rafts for treatment of asthma

    Amount: $599,929.00

    PROJECT SUMMARY Asthma, characterized by airways obstruction with symptoms of wheezing, shortness of breath, chest tightness and consequently cough, remains a significant health problem. While advance ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
  6. Targeting lipid rafts for treatment of migraine

    Amount: $665,674.00

    PROJECT SUMMARY Migraine is a highly prevalent condition with an extraordinarily negative impact on quality of life and represents a heavy socioeconomic burden to the societyprimarily because of decre ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government